CTLA4 and neoplasm: Strengths of our study include utilization of two large clinical trial datasets exploring CTLA-4 blockade in patients with advanced melanoma, collection of blood specimens prospectively in tubes optimized for mRNA preservation, the uniform follow-up of patients with clinical-trial level adverse event data capture, and the derivation of the biomarker from blood samples as opposed to more difficult to obtain colonic or tumor tissue biopsies.